Need professional-grade analysis? Visit stockanalysis.com
$1.42B
N/A
N/A
N/A
Oculis Holding AG Ordinary shares (OCS) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $27.38, down 0.29% from the previous close.
Over the past year, OCS has traded between a low of $16.13 and a high of $29.99. The stock has gained 53.0% over this period. It is currently 8.7% below its 52-week high.
Oculis Holding AG Ordinary shares has a market capitalization of $1.42B.
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Side-by-side comparison against top Healthcare peers.